Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 1
2012 1
2013 1
2015 5
2016 7
2017 4
2018 4
2019 4
2020 1
2021 4
2022 4
2023 6
2024 14
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigators. Lu S, et al. N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828946 Clinical Trial.
Primary gastric choriocarcinoma.
Ates O, Altundag K, Gullu I. Ates O, et al. J BUON. 2018 Mar-Apr;23(2):534. J BUON. 2018. PMID: 29745105 No abstract available.
Vortex keratopathy associated with ribociclib.
Türkel A, Özdoğan S, Yekedüz E, Şeyran E, Karaçin C, Ateş Ö. Türkel A, et al. Among authors: ates o. J Oncol Pharm Pract. 2023 Jan;29(1):230-232. doi: 10.1177/10781552221101799. Epub 2022 May 16. J Oncol Pharm Pract. 2023. PMID: 35570741
Sinonasal Cancers: Single Center Experience.
Camoz ES, Ates O, Kilic C, Goksel F, Akkas EA, Onur ID, Karacin C, Arslan UY. Camoz ES, et al. Among authors: ates o. Indian J Otolaryngol Head Neck Surg. 2025 Aug;77(8):2759-2765. doi: 10.1007/s12070-025-05531-3. Epub 2025 May 28. Indian J Otolaryngol Head Neck Surg. 2025. PMID: 40727179
HIPEC in Ovarian Cancer: When and to Whom?
Ates O, Aksel B, Akkus MH, Oner I, Yuksel C, Dogan M. Ates O, et al. J Coll Physicians Surg Pak. 2023 Sep;33(9):1001-1005. doi: 10.29271/jcpsp.2023.09.1001. J Coll Physicians Surg Pak. 2023. PMID: 37691361
Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study.
Akturk Esen S, Seven I, Akdere Ates G, Colak R, Kinikoglu O, Akay Hacan B, Bakkal Temi Y, Sever N, Kahraman S, Arak H, Topcu A, Saray S, Akbas S, Beypinar İ, Acar O, Erdoğan AP, Yilmaz M, Isik D, Ates O, Cabuk D, Sendur MAN, Uncu D. Akturk Esen S, et al. Among authors: ates o. Anticancer Drugs. 2025 Aug 1;36(7):575-582. doi: 10.1097/CAD.0000000000001717. Epub 2025 Apr 1. Anticancer Drugs. 2025. PMID: 40162996
65 results